What outcome after the prescription of neoadjuvant chemotherapy in lung cancer?

Background The treatment of patients with locally advanced non-small-cell lung cancer is controversial. Surgery remains the gold standard, even in this group. Neoadjuvant chemotherapy could allow surgical resection in patients initially judged inoperable. Methods From January 2009 to May 2010, neoad...

Full description

Saved in:
Bibliographic Details
Published in:Asian cardiovascular & thoracic annals 2013-08, Vol.21 (4), p.432-436
Main Authors: Boudaya, Mohamed-Sadok, Smadhi, Hanène, Marghli, Adel, Charmiti, Fatma, Ouerghi, Sonia, Mohamed, Jalel, Brahem, Emna, Smati, Belhassen, Mestiri, Taher, Kilani, Tarek
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - pathology
Carcinoma, Non-Small-Cell Lung - surgery
Chemotherapy, Adjuvant
Cisplatin - administration & dosage
Deoxycytidine - administration & dosage
Deoxycytidine - analogs & derivatives
Disease Progression
Female
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - pathology
Lung Neoplasms - surgery
Male
Middle Aged
Neoadjuvant Therapy
Neoplasm Staging
Patient Selection
Pneumonectomy
Retrospective Studies
Time Factors
Treatment Outcome
Vinblastine - administration & dosage
Vinblastine - analogs & derivatives
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The treatment of patients with locally advanced non-small-cell lung cancer is controversial. Surgery remains the gold standard, even in this group. Neoadjuvant chemotherapy could allow surgical resection in patients initially judged inoperable. Methods From January 2009 to May 2010, neoadjuvant chemotherapy was indicated in 27 patients with NSCLC (25 men, 2 women). Their mean age was 65 years. The stages were: IIB in 5, IIIA in 17 (6 in stage IIIAN2), IIIB in 2, and IV in 3. Results 23 patients received neoadjuvant chemotherapy, 2 refused induction treatment, and 2 had impaired status. The neoadjuvant chemotherapy regimen was gemcitabine-cisplatin in 17 patients and vinorelbine-cisplatin in 6. Only 5 patients underwent complete surgical treatment after induction: 1 in stage IIB, 1 in stage IIIAN0, 1 in IIIB, and 2 in stage IV (1 operated brain metastasis, and 1 operated adrenal metastasis). Surgical treatment was not achieved after neoadjuvant chemotherapy in 18 patients because of progressive disease. Conclusion Neoadjuvant chemotherapy offers several potential benefits, but it may delay surgery or eliminate eligibility as a surgical candidate. Rigorous patient selection for this type of multimodal treatment is essential.
ISSN:0218-4923
1816-5370
DOI:10.1177/0218492312462576